dc.contributor.author | Lim, JS | |
dc.contributor.author | Sundar, R | |
dc.contributor.author | Chénard-Poirier, M | |
dc.contributor.author | Lopez, J | |
dc.contributor.author | Yap, TA | |
dc.date.accessioned | 2017-03-01T17:27:28Z | |
dc.date.issued | 2017-01 | |
dc.identifier.citation | Biomarkers in medicine, 2017, 11 (1), pp. 53 - 67 | |
dc.identifier.issn | 1752-0363 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/461 | |
dc.identifier.eissn | 1752-0371 | |
dc.identifier.doi | 10.2217/bmm-2016-0228 | |
dc.description.abstract | The field of immuno-oncology has witnessed unprecedented success in recent years, with several PD=1 and PD-L1 inhibitors obtaining US FDA registration and breakthrough drug therapy designation in multiple tumor types. Despite its clear efficacy in certain cancers, treatment with these agents carries a risk of immune-related toxicities and substantial financial burden. It is, therefore, critical to identify patients likely to benefit from such immunotherapies and develop strategies to differentiate responders from nonresponders early during treatment. Here we discuss the development of predictive and treatment response biomarkers for immune checkpoint inhibitors. We first examine the role of PD-L1 expression, the most extensively studied predictive biomarker of response, and further discuss emerging putative predictive biomarkers. We also detail challenges faced in the development of response assessments for immunotherapeutics and propose other biomarkers that may be useful as surrogate intermediate end points of response. | |
dc.format | Print-Electronic | |
dc.format.extent | 53 - 67 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Neoplasms | |
dc.subject | Antibodies, Monoclonal | |
dc.subject | Antigens, Neoplasm | |
dc.subject | Immunotherapy | |
dc.subject | Predictive Value of Tests | |
dc.subject | Biomarkers | |
dc.subject | B7-H1 Antigen | |
dc.subject | Nivolumab | |
dc.title | Emerging biomarkers for PD-1 pathway cancer therapy. | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.2217/bmm-2016-0228 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2017-01 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Biomarkers in medicine | |
pubs.issue | 1 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 11 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Medicine (de Bono Prostate) | en_US |
icr.researchteam | Medicine Drug Development Unit (de Bono) | en_US |
dc.contributor.icrauthor | Yap, Timothy | en |
dc.contributor.icrauthor | Lopez, Juanita | en |
dc.contributor.icrauthor | Marsden, | en |